Arcturus Therapeutics

Arcturus Therapeutics is a preclinical drug delivery and RNA medicines company. We are focused on developing novel technologies to build the next generation of safe, effective RNA and DNA medicines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics.

Placeholder

Arcturus Therapeutics

  • Arcturus Therapeutics Expands Platform with STARR™ TechnologyREAD MORE
  • Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis FoundationREAD MORE
  • Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License AgreementREAD MORE
  • Synthetic GenomicsArcturus Therapeutics Announces Strategic Alliance with Synthetic Genomics, Inc. to develop self-amplifying RNA-based vaccines and therapeuticsREAD MORE
  • Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA MedicinesREAD MORE

LUNAR®-mediated delivery of RNA into cells

LUNAR particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis.

Upon entering the cytosol, the LUNAR formulations then become trapped in the endosomes.

With increased acidity as the endosome ages, a pH-mediated disruption enables release of the RNA payload following rapid biodegradation of the LUNAR components.

Once release of the RNA into the cytosol occurs, the translational machinery can interact with the RNA and processing and/or trafficking can then take place to make functional protein.

LUNAR® lipid mediated delivery enables delivery of RNA medicines.

News & Events

  • March 27, 2020

    Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System

    • March 27 2020
    • 0
    read more
  • March 11, 2020

    Arcturus Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results

    • March 11 2020
    • 0
    read more
  • March 4, 2020

    Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ Technology

    • March 4 2020
    • 0
    read more
  • February 25, 2020

    Arcturus Therapeutics to Report Fourth Quarter and Year-End 2019 Financial Results and Provide Corporate Update on March 11

    • February 25 2020
    • 0
    read more
  • February 19, 2020

    Arcturus Therapeutics to Present at Two Investor Conferences in March

    • February 19 2020
    • 0
    read more
  • January 8, 2020

    Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer

    • January 8 2020
    • 0
    read more
  • November 7, 2019

    Arcturus Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

    • November 7 2019
    • 0
    read more
  • November 7, 2019

    Arcturus Therapeutics Expands Platform with STARR™ Technology

    • November 7 2019
    • 0
    read more
  • November 4, 2019

    Arcturus Therapeutics to Report Corporate Overview and Financial Results on November 7th

    • November 4 2019
    • 0
    read more